BetterLife Pharma (STU:NPAU) EBIT : €-1.94 Mil (TTM As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BetterLife Pharma EBIT?

BetterLife Pharma's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2024 was €-0.45 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2024 was €-1.94 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BetterLife Pharma's annualized ROC % for the quarter that ended in Jan. 2024 was -899.10%. BetterLife Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BetterLife Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -17.99%.

BetterLife Pharma EBIT Historical Data

The historical data trend for BetterLife Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma EBIT Chart

BetterLife Pharma Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

EBIT

Get a 7-Day Free Trial

-13.19

-23.43

-8.36

-6.43

-1.95

BetterLife Pharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBIT	Get a 7-Day Free Trial															-0.40	-0.65	-0.70	-0.14	-0.45

Competitive Comparison of BetterLife Pharma's EBIT

For the Biotechnology subindustry, BetterLife Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BetterLife Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's EV-to-EBIT falls into.

BetterLife Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.94 Mil.

BetterLife Pharma (STU:NPAU) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BetterLife Pharma's annualized ROC % for the quarter that ended in Jan. 2024 is calculated as:

	ROC % (Q: Jan. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2023 )	+	Invested Capital (Q: Jan. 2024 ))	/ count )
=	-1.996 * ( 1 - 0% )	/	( (0.064	+	0.38)	/ 2 )
=	-1.996	/	0.222
=	-899.10 %

where

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.352	-	4.343	-	( 0.064	-	max(0, 4.407	-	0.352	+	0.064	))
=	0.064

	Invested Capital		(Q: Jan. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.222	-	4.289	-	( 0.025	-	max(0, 4.669	-	0.222	+	0.025	))
=	0.38

Note: The Operating Income data used here is four times the quarterly (Jan. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BetterLife Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2023		Q: Jan. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.796	/	( ( (0 + max(-4.064, 0))	+	(0 + max(-4.096, 0)) )	/	2 )
=	-1.796	/	( ( 0	+	0 )	/	2 )
=	-1.796	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Oct. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.009	+	0	+	0.279)	-	(4.343	+	0	+	0.0090000000000003)
=	-4.064

	Working Capital		(Q: Jan. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.027	+	0	+	0.17)	-	(4.289	+	0	+	0.0039999999999996)
=	-4.096

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BetterLife Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jan. 2024 )
	=	-1.942	/	10.795
	=	-17.99 %

BetterLife Pharma EBIT Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma (STU:NPAU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (STU:NPAU) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

BETRF:USA NPAU:Germany BETR:Canada

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

BetterLife Pharma (STU:NPAU) Headlines

No Headlines